Anastrozole (Arimidex):
The Complete Canadian AI Guide
Anastrozole (Arimidex) is one of the most precise and potent aromatase inhibitors available to Canadian athletes managing estrogen-related side effects on cycle. A third-generation, non-steroidal AI that selectively and reversibly inhibits the aromatase enzyme, Anastrozole delivers powerful estrogen suppression to prevent gynecomastia, control water retention, and optimise the testosterone-to-estrogen ratio during anabolic steroid cycles. This is the complete Canadian guide to Anastrozole: from mechanism to dosing, on-cycle integration to side effect management, and every critical AI decision you need to make correctly.
What Is Anastrozole (Arimidex)?
Anastrozole, marketed under the brand name Arimidex by AstraZeneca, is a third-generation, non-steroidal aromatase inhibitor (AI) approved clinically for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Within Canada’s performance enhancement community, it serves an entirely different but equally important purpose: it is the most widely used on-cycle aromatase inhibitor for managing estrogen-related side effects in athletes running anabolic steroid cycles that aromatise to estrogen.
Anastrozole operates through a fundamentally different mechanism than SERMs like Nolvadex or Clomid. Where SERMs block estrogen from binding to its receptors at target tissues, Anastrozole attacks the problem upstream: it directly inhibits the aromatase enzyme (CYP19A1) responsible for converting androgens like testosterone into estradiol. By suppressing estrogen at the point of synthesis rather than at the point of receptor binding, Anastrozole reduces circulating estrogen levels throughout the entire body, providing systemic estrogen control that SERMs simply cannot achieve.
The clinical superiority of third-generation AIs like Anastrozole over their predecessors is well-established. First-generation AIs like aminoglutethimide caused widespread adrenal suppression. Second-generation compounds like formestane required injection. Anastrozole delivers potent, selective aromatase inhibition in a convenient once-daily oral form, with a selectivity profile that spares other steroidogenic pathways and a reversibility that allows the aromatase enzyme to resume full function when the drug is discontinued — a critical feature for Canadian athletes who need estrogen levels to normalise post-cycle during PCT.
Clinical pharmacology data confirm that a single 1 mg oral dose of Anastrozole suppresses plasma estradiol by approximately 80% within 24 hours in postmenopausal women. In eugonadal men running exogenous testosterone, the aromatase suppression Anastrozole delivers prevents the supraphysiological estradiol elevations that drive gynecomastia development, water retention, blood pressure elevation, and libido disruption during anabolic cycles. This makes it an indispensable tool for Canadian athletes running testosterone-based cycles at doses sufficient to produce meaningful aromatisation.
Regarding Canadian legal status: Anastrozole is a prescription medication under Canada’s Food and Drugs Act. It is not a controlled substance under the Controlled Drugs and Substances Act, meaning possession without a prescription is not a criminal offence, though acquiring it without one occupies a legal grey area. It is widely available through Canadian online research chemical suppliers and domestic pharmaceutical channels. WADA prohibits Anastrozole for male athletes in competition under the Hormone and Metabolic Modulators category, an important consideration for Canadian athletes competing in tested sports who must calculate clearance timing carefully before competition.
- Chemical NameAnastrozole
- Brand NameArimidex
- Drug ClassNon-Steroidal AI
- Half-Life40–50 hours
- AdministrationOral · Once Daily or EOD
- Standard Dose0.5–1 mg / day or EOD
- Estradiol SuppressionUp to 80% at 1 mg/day
- Primary UseOn-Cycle Estrogen Control
- Gyno PreventionExcellent
- Water Retention ControlExcellent
- Bone Density RiskYes · Long-Term Use
- Lipid ImpactModerate · HDL Reduction
- Reversible InhibitionYes
- WADA Status (Men)Prohibited In-Competition
- Rx Required CanadaTechnically Yes
- Clinical EvidenceExtensive
How Anastrozole Controls Estrogen on Cycle
Anastrozole’s on-cycle effectiveness is driven by four interconnected physiological mechanisms that work together to suppress estradiol synthesis, prevent aromatisation-driven side effects, and maintain the optimal hormonal environment for muscle growth and performance during anabolic steroid use.
Selective Aromatase Enzyme Inhibition
Anastrozole binds selectively and reversibly to the aromatase enzyme (CYP19A1), the enzyme responsible for the conversion of androgens — including testosterone, androstenedione, and DHEA — into estrogens. By occupying the enzyme’s active site, Anastrozole prevents the aromatisation reaction from occurring, reducing estradiol synthesis in peripheral tissues including adipose tissue, muscle, liver, and the adrenal glands. This upstream intervention reduces circulating estradiol systemically rather than merely blocking its effects at individual receptor sites, producing whole-body estrogen suppression that is pharmacologically distinct from what SERMs can deliver.
Systemic Estradiol Level Reduction
The consequence of aromatase inhibition is a measurable, dose-dependent reduction in circulating estradiol levels. At the standard 1 mg/day clinical dose, Anastrozole suppresses plasma estradiol by approximately 80% in postmenopausal women. In male athletes running exogenous testosterone at performance-enhancing doses, the effective estradiol suppression allows total and free testosterone to remain elevated while keeping estradiol within the physiological range where benefits — including libido, cardiovascular health, joint lubrication, and mood stability — are maintained without the supraphysiological estradiol elevations that drive gynecomastia and water retention.
Gynecomastia and Water Retention Prevention
The two most immediately consequential estrogen-related side effects of anabolic steroid use for Canadian athletes are gynecomastia and water retention. Both are directly driven by elevated estradiol stimulating estrogen receptors in breast tissue and the renal tubules respectively. Anastrozole’s suppression of estradiol synthesis addresses both simultaneously: preventing the estrogenic stimulus that drives breast tissue proliferation and the fluid retention that produces the soft, bloated appearance that blunts visual muscle definition during bulking cycles. This dual cosmetic and health benefit is the primary reason Anastrozole has become the default on-cycle AI for Canadian athletes.
Testosterone-to-Estrogen Ratio Optimisation
Beyond preventing specific side effects, Anastrozole contributes to optimising the overall testosterone-to-estrogen ratio during anabolic cycles. An optimal T:E ratio supports the androgenic effects of the cycle — muscle protein synthesis, nitrogen retention, red blood cell production, and recovery — without the suppressive effects that excessive estradiol can exert on the male hormonal environment. Critically, however, Anastrozole must be dosed carefully: over-suppression of estradiol is a common and consequential error among Canadian athletes, producing joint pain, libido loss, mood disruption, and adverse lipid changes that are as harmful to cycle quality as excessive estrogen itself.
Why Canadian Athletes Choose Anastrozole
Anastrozole offers a distinct set of advantages over other estrogen management strategies that make it the on-cycle AI of choice for Canadian athletes running aromatising anabolic steroids. Understanding these advantages — and their limitations — is essential for informed, effective estrogen management during Canadian performance cycles.
Most Potent Oral AI Available to Canadian Athletes
Among the aromatase inhibitors available to Canadian athletes — Anastrozole, Exemestane, and Letrozole — Anastrozole occupies the middle ground of potency and is the most widely used due to its well-characterised dose-response profile and convenient oral bioavailability. It is significantly more potent than older, first-generation AIs and delivers the estrogen suppression required to manage even moderate to high-dose testosterone cycles, making it effective across the full spectrum of Canadian performance cycle intensities from beginner test-only to advanced multi-compound programmes.
Systemic Estrogen Control Across All Tissues
Unlike SERMs, which only block estrogen at specific receptor sites while leaving circulating estradiol levels elevated, Anastrozole reduces estradiol throughout the entire body by inhibiting its synthesis. This systemic suppression provides more comprehensive protection against estrogen-driven side effects that occur across multiple tissue types simultaneously — breast tissue, vascular endothelium, renal tubules, and adipose tissue — than receptor-level blockade alone can achieve. For Canadian athletes running aromatising compounds at performance doses, this whole-body estrogen control is a categorical advantage over SERM-only estrogen management strategies.
Reversible Inhibition Supports Post-Cycle Recovery
Anastrozole’s reversible, non-covalent binding to the aromatase enzyme means that when the drug is discontinued, the enzyme resumes full function promptly as Anastrozole clears the system. This reversibility is important for Canadian athletes transitioning into PCT: estradiol production can normalise appropriately as the HPTA begins recovering under SERM stimulation, avoiding the prolonged estrogen suppression that steroidal AIs like Exemestane produce through permanent enzyme inactivation. Proper timing of Anastrozole discontinuation — typically at the start of PCT rather than continued through it — supports the optimal hormonal environment for HPTA recovery.
Convenient Oral Administration With Long Half-Life
Anastrozole’s 40 to 50 hour half-life allows flexible dosing schedules that fit easily into Canadian athletes’ on-cycle routines without complex multi-daily administration requirements. Standard protocols involve taking Anastrozole either daily or every other day, with the long half-life ensuring that stable plasma concentrations are maintained on either schedule. This combination of oral convenience and pharmacokinetic stability eliminates the compliance burden that injectable or short-acting AI compounds would impose, making consistent estrogen control throughout a full cycle straightforward for Canadian athletes to maintain.
Decades of Safety Data From Clinical Use
Anastrozole has been in widespread clinical use since its approval in the mid-1990s, generating an extensive safety and pharmacology database that gives Canadian athletes a well-characterised compound with predictable behaviour at therapeutic and sub-therapeutic doses. The clinical literature on Anastrozole in male secondary hypogonadism and fertility treatment provides additional directly applicable safety and efficacy data beyond the breast cancer indication. This depth of clinical evidence base is a meaningful advantage over newer or less studied estrogen management strategies that lack the same long-term characterisation of their risk profiles at the doses relevant to athletic use.
Widely Available Across Canada’s Research Market
Despite its prescription classification, Anastrozole is consistently available to Canadian athletes through domestic research chemical suppliers and grey-market pharmaceutical channels across all major Canadian provinces. Its established role in the Canadian performance enhancement community means that quality-assessed sources are identifiable and consistent supply can be secured before cycle initiation — which, as with all cycle support compounds, is the correct approach. Canadian athletes should never begin a cycle that will require estrogen management without having their AI already on hand from a verified source.
Anastrozole vs Exemestane vs Letrozole: Choosing Your AI
Canadian athletes have three primary aromatase inhibitors available for on-cycle estrogen management, each with a distinct pharmacological profile, potency level, and practical trade-offs. This comparison helps Canadian athletes match the right AI to their specific cycle, goals, and risk tolerance.
| Factor | Anastrozole (Arimidex) | Exemestane (Aromasin) | Letrozole (Femara) |
|---|---|---|---|
| AI Type | Non-steroidal · Reversible | Steroidal · Irreversible | Non-steroidal · Reversible |
| Estradiol Suppression | Strong · ~80% at 1mg | Moderate · ~85% at 25mg | Very Strong · ~98% at 2.5mg |
| Androgenic Activity | None | Mild anabolic / androgenic | None |
| HDL Cholesterol Impact | Moderate reduction | Minimal · Favourable | Significant reduction |
| Crash Risk (Over-Suppression) | Moderate · Dose-dependent | Lower · Self-limiting | High · Very easy to crash |
| Best For | Most cycles · First AI | Lipid-sensitive athletes | Gyno treatment · Heavy aromatisers |
| Standard Cycle Dose | 0.5mg EOD to 1mg/day | 12.5–25mg EOD to daily | 0.5mg EOD · Use cautiously |
| SERM Interaction | Reduced by Tamoxifen | No negative SERM interaction | Reduced by Tamoxifen |
| Beginner Recommended | Yes · First choice | Yes · Good second choice | No · Advanced use only |
Complete Anastrozole On-Cycle Dosage Guide
Anastrozole dosing is calibrated to aromatisation load, which is primarily determined by the testosterone dose and the presence of other aromatising compounds in the cycle. Starting conservatively and adjusting based on bloodwork and symptom monitoring is the correct approach for every Canadian athlete.
Critical note on AI timing and dose adjustment: Anastrozole should not be started at the beginning of week one of a testosterone cycle in most cases. For long-ester cycles using Testosterone Enanthate or Cypionate, it takes approximately two to four weeks for blood levels to stabilise and aromatisation to accelerate. Beginning Anastrozole in week two to three with a conservative 0.5 mg every other day dose allows estradiol to be managed reactively rather than pre-emptively crashing it before any meaningful aromatisation has occurred. All dose adjustments should ideally be guided by mid-cycle bloodwork measuring estradiol and the athlete’s subjective experience of estrogen-related or low-estrogen symptoms. Important Tamoxifen interaction note: Anastrozole’s efficacy is meaningfully reduced when co-administered with Tamoxifen (Nolvadex). Canadian athletes using Nolvadex as a PCT SERM should discontinue Anastrozole at the start of PCT rather than running both compounds simultaneously.
Anastrozole in Canada: Regulations, Access and Costs
Understanding Anastrozole’s legal and regulatory landscape in Canada helps athletes make informed decisions about access, sourcing, and responsible use within the Canadian healthcare and legal framework.
Canadian Regulatory Classification
- → Prescription drug under the Food and Drugs Act
- → Not a controlled substance under CDSA
- → Possession without Rx: legal grey area
- → WADA prohibited for male athletes in-competition
Anastrozole is regulated by Health Canada as a Schedule I prescription drug. Unlike anabolic steroids, which are Schedule IV controlled substances, Anastrozole’s non-controlled status means possession without prescription is not a criminal offence under Canadian law, though obtaining it outside the prescription system occupies a regulatory grey area that athletes should understand clearly.
Sourcing Anastrozole in Canada
- → Available at licensed Canadian pharmacies with Rx
- → Widely stocked by domestic research chemical suppliers
- → Generic versions widely available and cost-effective
- → Provincial drug benefit coverage varies by programme
The cost of Anastrozole in Canada varies significantly based on whether brand-name Arimidex or generic Anastrozole is sourced, the province of purchase, and insurance or provincial drug benefit programme coverage. Generic Anastrozole is substantially more affordable than branded Arimidex and is pharmacologically identical, making it the practical choice for Canadian athletes managing cycle support costs.
WADA Status and Clearance
- → Prohibited in-competition for male athletes
- → Category: Hormone and Metabolic Modulators
- → Half-life 40–50 hours: plan clearance carefully
- → Detection windows vary by testing method and dose
Canadian athletes competing in WADA-governed sports must approach Anastrozole use with particular care regarding in-competition clearance. Despite its 40 to 50 hour half-life suggesting relatively rapid clearance compared to some compounds, sophisticated modern anti-doping testing can detect Anastrozole and its metabolites for periods extending beyond simple half-life calculations. Consultation with a sports medicine physician is strongly advisable for competitive Canadian athletes.
Managing Anastrozole’s Side Effects: The Canadian Athlete’s Guide
Anastrozole’s side effects in athletic use arise almost exclusively from one source: excessive estrogen suppression. Understanding the signs of estradiol over-suppression — the estrogen crash — is the most critical risk management skill for Canadian athletes using Anastrozole on cycle.
The Estrogen Crash: The Most Important Risk
The single most consequential Anastrozole-related side effect in athletic use is driving estradiol too low. Canadian athletes who use Anastrozole too aggressively — starting too early, dosing too frequently, or using too high a dose — risk suppressing estradiol below the physiological range that supports healthy male function. Symptoms of estrogen crash include severe joint pain, complete libido loss, erectile dysfunction, profound fatigue, depression, brain fog, and insomnia. These symptoms can be more debilitating during a cycle than the estrogenic side effects the Anastrozole was meant to prevent. The correct response is to immediately reduce or temporarily discontinue Anastrozole and allow estradiol to recover before resuming at a lower dose.
Lipid Profile Deterioration
Estrogen plays an important protective role in cardiovascular health in both men and women, and Anastrozole’s suppression of estradiol extends to suppressing estrogen’s beneficial effects on lipid metabolism. At standard on-cycle doses, Anastrozole produces a measurable reduction in HDL cholesterol that compounds the adverse lipid changes already produced by anabolic steroid use. Canadian athletes with pre-existing lipid concerns, a family history of cardiovascular disease, or those running long cycles should monitor lipid panels during Anastrozole use and consider Exemestane as an alternative AI with a more favourable lipid impact profile. Cardiovascular support supplementation including omega-3 fatty acids is advisable for all Canadian athletes using Anastrozole on cycle.
Bone Mineral Density Reduction
Estradiol is a critical regulator of bone metabolism in males, and long-term suppression of estradiol by aromatase inhibitors in clinical populations is associated with reduced bone mineral density and increased fracture risk. For Canadian athletes using Anastrozole for the duration of typical performance cycles of eight to sixteen weeks, this risk is unlikely to be clinically significant in isolation. However, athletes who run back-to-back cycles with continuous Anastrozole use, or who use Anastrozole at high doses for extended periods, should be aware of the cumulative bone density implications and consider adequate calcium and vitamin D3 supplementation throughout all periods of Anastrozole use as a basic mitigation measure.
Hot Flashes and Vasomotor Symptoms
Hot flashes, driven by hypothalamic thermoregulatory disruption secondary to estradiol suppression, are commonly reported by female breast cancer patients using Anastrozole at clinical doses and can also occur in male athletes, particularly at doses that produce significant estradiol suppression. In the athletic context, hot flashes during Anastrozole use are most commonly a signal of over-suppression rather than a benign side effect to be tolerated through. Canadian athletes experiencing hot flashes during Anastrozole use should treat them as an indicator to reduce dose rather than simply manage the symptom, as they typically reflect estradiol levels that have dropped below the optimal range for male physiological function and cycle quality.
Pro Tips for Running Anastrozole Correctly on Cycle
Effective Anastrozole use requires more than simply taking the compound throughout a cycle. These are the most important practical insights from experienced Canadian athletes that consistently separate well-managed, productive cycles from those derailed by estrogen-related problems in either direction.
📈 Bloodwork Guides Everything — Symptoms Alone Are Unreliable
The symptoms of high estrogen and the symptoms of low estrogen overlap significantly in male athletes: libido issues, mood changes, and fatigue can result from either extreme. Without an estradiol blood test result to anchor your interpretation, adjusting Anastrozole dose based on symptoms alone risks moving in the wrong direction. Mid-cycle bloodwork measuring estradiol — ideally using the sensitive assay validated for males — provides the objective data point that allows Canadian athletes to confirm whether their Anastrozole dose is producing appropriate suppression, under-suppression requiring dose increase, or over-suppression requiring dose reduction. Private lab testing is readily available across Canada without a physician referral.
🚫 Do Not Run Anastrozole Through PCT With Nolvadex
A pharmacokinetic interaction between Anastrozole and Tamoxifen (Nolvadex) reduces the plasma concentration of both compounds when co-administered. Canadian athletes who plan Nolvadex-based PCT should discontinue Anastrozole when beginning PCT rather than continuing both simultaneously. During PCT, some estradiol elevation is physiologically appropriate and actually supportive of HPTA recovery, since estrogen plays a role in the feedback signalling that the recovering axis uses. Continuing Anastrozole through PCT risks suppressing the estradiol needed for complete recovery while simultaneously reducing Nolvadex’s effectiveness through the drug interaction. Anastrozole ends when the cycle ends. PCT begins when ester clearance is complete.
🎯 Start Conservative — You Can Always Increase
The most experienced Canadian athletes universally recommend starting Anastrozole at the lowest effective dose and titrating upward based on response rather than beginning aggressively and trying to walk back an estrogen crash. Beginning with 0.5 mg every other day on a moderate testosterone cycle allows the aromatase to be partially inhibited without risking over-suppression during the dose establishment phase. If estrogen-related symptoms develop — nipple sensitivity, significant water retention, blood pressure elevation — the dose can be increased to 0.5 mg daily or 1 mg every other day incrementally. This conservative titration approach prevents the estrogen crash scenario that starting at 1 mg daily on a first cycle produces for many Canadian athletes.
💉 Source Your AI Before Your First Injection
No Canadian athlete should administer the first dose of an aromatising anabolic steroid without Anastrozole (or an alternative AI) already on hand, sourced from a verified supplier, and ready to use. Aromatisation begins with the first dose of exogenous testosterone and accelerates as blood levels rise through weeks two to four of a cycle. The scenario of reaching week three of a Testosterone Enanthate cycle with rising nipple sensitivity and no AI available is entirely preventable and represents a failure of basic cycle preparation. Purchase AI before cycle start. Store it correctly. Use it as needed based on bloodwork and symptom monitoring. This is the baseline standard for responsible Canadian cycle management.
🧠 Understand That Not Everyone Needs an AI on Every Cycle
A meaningful percentage of Canadian athletes — particularly those with lower natural aromatisation rates, running lower testosterone doses, or using non-aromatising compounds — do not develop significant estrogenic side effects and do not require prophylactic Anastrozole use throughout their cycle. Running Anastrozole when it is not needed suppresses estradiol below the optimal physiological range for male health without providing any protective benefit in return, producing the side effects of an AI without the benefits. Canadian beginners running their first testosterone cycle at 300 to 400 mg per week should have Anastrozole available on hand but should consider beginning it only if and when estrogenic symptoms develop, rather than as a mandatory addition from day one regardless of individual response.
🏃 Maintain Cardiovascular Support Throughout AI Use
The combined lipid impact of anabolic steroid use and Anastrozole-driven estrogen suppression creates a more challenging cardiovascular environment than either factor alone. Canadian athletes using Anastrozole on cycle should prioritise cardiovascular support as a non-negotiable component of their complete cycle support protocol: omega-3 fatty acids at four to six grams daily to support HDL and triglyceride management, regular cardiovascular exercise sessions maintained throughout the cycle, adequate hydration, blood pressure monitoring, and avoidance of additional HDL-suppressive factors including alcohol and extremely high saturated fat intake. Managing the cardiovascular side effect burden of AI use is as important as managing the hormonal side effects in the context of long-term Canadian athlete health.
Debunking the Biggest Anastrozole Myths
Persistent misconceptions about Anastrozole cause real harm to Canadian athletes who rely on accurate information to manage their cycles safely. Here is the evidence-based truth behind the most consequential Arimidex myths circulating in Canadian fitness and bodybuilding communities.
Myth 1: Every Testosterone Cycle Requires Anastrozole From Day One
Perhaps the most damaging blanket advice circulating in Canadian online steroid communities is that Anastrozole must be run prophylactically throughout every testosterone cycle regardless of individual response. This one-size-fits-all approach ignores the significant inter-individual variation in aromatisation rates, the dose-dependence of aromatisation, and the real harm that unnecessary estrogen suppression causes. Canadian athletes who run Anastrozole when they don’t need it are not managing risk; they are creating a different set of risks including joint deterioration, libido loss, mood disruption, and adverse lipid changes.
- → Aromatisation rates vary significantly between individuals based on genetics, body composition, and testosterone dose
- → Many athletes running 400 mg/week of Testosterone Enanthate experience no significant estrogenic side effects without AI
- → Unnecessary AI use suppresses the estradiol needed for joint health, libido, mood, and cardiovascular function
Myth 2: Higher Anastrozole Doses Provide Better Cycle Results
The misconception that maximally suppressing estrogen during an anabolic cycle produces the best results — leaner appearance, more muscle hardness, better gains — leads some Canadian athletes to run Anastrozole at doses of 1 mg daily or higher throughout entire cycles. Estrogen is not the enemy of muscle growth; it is a required co-factor in numerous anabolic processes. Insulin-like Growth Factor-1 (IGF-1) production, muscle glycogen storage, nitrogen retention, and joint tissue health all benefit from physiologically appropriate estradiol levels. Crushing estrogen to undetectable levels with high-dose Anastrozole during a muscle-building cycle actively undermines the very outcomes the cycle is designed to produce.
- → Estradiol supports IGF-1 production, which is anabolic and critical to cycle gains
- → Physiological estrogen levels are required for healthy joint lubrication, preventing the pain that disrupts training
- → Estradiol supports mood, motivation, libido, and sleep — all of which directly affect training quality and recovery
Myth 3: Anastrozole Should Be Continued Through PCT to Control Estrogen Rebound
Some Canadian athletes continue Anastrozole into their PCT period, believing this prevents an estrogen rebound that will impair HPTA recovery. This practice is counterproductive for two reasons: first, the Anastrozole-Tamoxifen interaction reduces the efficacy of Nolvadex-based PCT when both are co-administered. Second, during the PCT period, the recovering HPTA actually benefits from the rising estradiol that accompanies improving testosterone production, since estrogen plays a role in the hypothalamic feedback signals that drive further GnRH pulsatility and gonadotropin release. Suppressing estradiol during PCT removes part of the physiological machinery needed for complete HPTA restoration.
- → Tamoxifen and Anastrozole co-administration reduces plasma concentrations of both compounds
- → Rising estradiol during PCT is a sign of successful testosterone recovery, not a problem requiring suppression
- → Physiological estradiol levels during PCT support mood, libido, and the hypothalamic function required for recovery
Anastrozole: The On-Cycle AI Tool
Every Canadian Athlete Should Use Correctly
Anastrozole (Arimidex) occupies an essential and non-negotiable position in responsible Canadian cycle management for athletes running aromatising anabolic steroids. It is the most widely used, best-characterised, and most practically accessible aromatase inhibitor available in Canada, with decades of clinical evidence underpinning its safety and efficacy at the doses relevant to athletic use. It is also a compound that demands respect, precision, and a firm understanding that its purpose is estrogen optimisation — not estrogen elimination. The Canadian athletes who run Anastrozole most effectively are those who use bloodwork to guide their dosing, start conservatively and titrate based on objective data, understand the pharmacokinetic interaction with Nolvadex that makes it incompatible with Tamoxifen-based PCT, and have their AI sourced and ready before their cycle begins rather than scrambling for it when estrogenic symptoms appear. Get your baseline bloodwork done. Source Anastrozole before your first injection. Start at 0.5 mg every other day and adjust based on mid-cycle estradiol results. Discontinue at cycle end when transitioning to PCT. Retest your bloodwork post-PCT. That is how responsible Canadian athletes use Anastrozole — and that is the standard that every cycle should be managed to.
